Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2016 1
2017 1
2018 4
2019 5
2020 4
2021 8
2022 5
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Nakagawa K, et al. Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4. Lancet Oncol. 2019. PMID: 31591063 Clinical Trial.
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.
Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA. Oxnard GR, et al. Among authors: mileham kf. JAMA Oncol. 2018 Nov 1;4(11):1527-1534. doi: 10.1001/jamaoncol.2018.2969. JAMA Oncol. 2018. PMID: 30073261 Free PMC article.
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
Duvivier HL, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Al Baghdadi T, Alva AS, Dublis SA, Cannon TL, Calfa CJ, Li R, Behl D, Chiu VK, Gold PJ, Marr AS, Mileham KF, Powell SF, Rodon J, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Duvivier HL, et al. Among authors: mileham kf. J Clin Oncol. 2023 Nov 20;41(33):5140-5150. doi: 10.1200/JCO.23.00702. Epub 2023 Aug 10. J Clin Oncol. 2023. PMID: 37561967
New targets and new mechanisms in lung cancer.
Carrizosa DR, Mileham KF, Haggstrom DE. Carrizosa DR, et al. Among authors: mileham kf. Oncology (Williston Park). 2013 May;27(5):396-404. Oncology (Williston Park). 2013. PMID: 25184262 Free article. Review.
Treatment of advanced squamous cell carcinoma of the lung: a review.
Derman BA, Mileham KF, Bonomi PD, Batus M, Fidler MJ. Derman BA, et al. Among authors: mileham kf. Transl Lung Cancer Res. 2015 Oct;4(5):524-32. doi: 10.3978/j.issn.2218-6751.2015.06.07. Transl Lung Cancer Res. 2015. PMID: 26629421 Free PMC article. Review.
Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report.
Thummalapalli R, Choudhury NJ, Ehrich F, Beardslee T, Brazel D, Zhang SS, Merchant S, Chen MF, Heller G, Ramalingam SS, Ou SI, Mileham KF, Riely GJ. Thummalapalli R, et al. Among authors: mileham kf. JTO Clin Res Rep. 2023 Jun 30;4(8):100546. doi: 10.1016/j.jtocrr.2023.100546. eCollection 2023 Aug. JTO Clin Res Rep. 2023. PMID: 37644967 Free PMC article.
31 results